Kancera AB (publ) announced that Dr. Markus Jerling has been appointed as new Chief Medical Officer, effective from September 1, 2023. Dr. Jerling has a PhD in clinical pharmacology and more than twenty-five years of experience of international drug development and has held various management positions in both Swedish and US companies. In addition to his experience of drug development in all clinical phases, he has fifteen years of experience from academic research and as a practising physician.

During the first half of 2023, Kancera has contracted Dr. Jerling as subject matter expert in the fields of drug safety and PK/PD in connection with the KANDOVA study. Dr. Jerling will initially assume a position as part time consultant. Dr. Hanjing Xie, Kancera's former CMO on a part-time consulting basis, is leaving the company and assuming a new position as CMO at Amal Therapeutics, a subsidiary of Boehringer Ingelheim headquartered in Geneva, Switzerland.